WO2008051176A1 - Method and system to control respiration by means of simulated neuro-electrical coded signals - Google Patents
Method and system to control respiration by means of simulated neuro-electrical coded signals Download PDFInfo
- Publication number
- WO2008051176A1 WO2008051176A1 PCT/US2006/007952 US2006007952W WO2008051176A1 WO 2008051176 A1 WO2008051176 A1 WO 2008051176A1 US 2006007952 W US2006007952 W US 2006007952W WO 2008051176 A1 WO2008051176 A1 WO 2008051176A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- signal
- subject
- signals
- electrical coded
- respiration
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/3601—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation of respiratory organs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/3605—Implantable neurostimulators for stimulating central or peripheral nerve system
- A61N1/3606—Implantable neurostimulators for stimulating central or peripheral nerve system adapted for a particular treatment
- A61N1/3611—Respiration control
Definitions
- the present invention relates generally to medical methods and systems for monitoring and controlling respiration. More particularly, the invention relates to a method and system for controlling respiration by means of simulated neuro-electrical coded signals.
- the brain modulates (or controls) respiration via electrical signals (i.e., action potentials or waveform signals), which are transmitted through the nervous system.
- the nervous system includes two components: the central nervous system, which comprises the brain and the spinal cord, and the peripheral nervous system, which generally comprises groups of nerve cells (i.e., neurons) and peripheral nerves that lie outside the brain and spinal cord.
- the two systems are anatomically separate, but functionally interconnected.
- the peripheral nervous system is constructed of nerve cells (or neurons) and glial cells (or glia), which support the neurons.
- Operative neuron units that carry signals from the brain are referred to as “efferent” nerves.
- “Afferent” nerves are those that carry sensor or status information to the brain.
- a typical neuron includes four morphologically defined regions: (i) cell body, (ii) dendrites, (iii) axon and (iv) presynaptic terminals.
- the cell body (soma) is the metabolic center of the cell.
- the cell body contains the nucleus, which stores the genes of the cell, and the rough and smooth endoplasmic reticulum, which synthesizes the proteins of the cell.
- the cell body typically includes two types of outgrowths (or processes); the dendrites and the axon. Most neurons have several dendrites; these branch out in treelike fashion and serve as the main apparatus for receiving signals from other nerve cells.
- the axon is the main conducting unit of the neuron.
- the axon is capable of conveying electrical signals along distances that range from as short as 0.1 mm to as long as 2 m. Many axons split into several branches, thereby conveying information to different targets.
- the axon is divided into fine branches that make contact with other neurons.
- the point of contact is referred to as a synapse.
- the cell transmitting a signal is called the presynaptic cell, and the cell receiving the signal is referred to as the postsynaptic cell.
- Specialized swellings on the axon's branches i.e., presynaptic terminals serve as the transmitting site in the presynaptic cell.
- axons terminate near a postsynaptic neuron's dendrites. However, communication can also occur at the cell body or, less often, at the initial segment or terminal portion of the axon of the postsynaptic cell.
- the diaphragm is a sheet-shaped muscle, which separates the thoracic cavity from the abdominal cavity.
- the diaphragm moves about 1 cm. However, in forced breathing, the diaphragm can move up to 10 cm. The left and right phrenic nerves activate diaphragm movement.
- Diaphragm contraction and relaxation accounts for approximately 75% volume change in the thorax during normal quiet breathing. Contraction of the diaphragm occurs during inspiration. Expiration occurs when the diaphragm relaxes and recoils to its resting position. All movements of the diaphragm and related muscles and structures are controlled by coded electrical signals traveling from the brain.
- the main nerves that are involved in respiration are the ninth and tenth cranial nerves, the phrenic nerve, and the intercostal nerves.
- the glossopharyngeal nerve (cranial nerve IX) innervates the carotid body and senses CO 2 levels in the blood.
- the vagus nerve (cranial nerve X) provides sensory input from the larynx, pharynx, and thoracic viscera, including the bronchi.
- the phrenic nerve arises from spinal nerves C3, C4, and C5 and innervates the diaphragm.
- the intercostal nerves arise from spinal nerves T7-11 and innervate the intercostal muscles.
- the various afferent sensory neuro-fibers provide information as to how the body should be breathing in response to events outside the body proper.
- vagus nerve and its preganglionic nerve fibers which synapse in ganglia.
- the ganglia are embedded in the bronchi that are also innervated with sympathetic and parasympathetic activity.
- the sympathetic nerve division can have no effect on bronchi or it can dilate the lumen (bore) to allow more air to enter during respiration, which is helpful to asthma patients, while the parasympathetic process offers the opposite effect and can constrict the bronchi and increase secretions, which can be harmful to asthma patients.
- Action potentials The electrical signals transmitted along the axon to control respiration, referred to as action potentials, are rapid and transient "all-or-none" nerve impulses.
- Action potentials typically have of approximately 100 millivolts (mV) and duration of approximately 1 msec.
- Action potentials are conducted along the axon, without failure or distortion, at rates in the range of approximately 1 - 100 meters/sec.
- the amplitude of the action potential remains constant throughout the axon, since the impulse is continually regenerated as it traverses the axon.
- a "neurosignal” is a composite signal that includes many action potentials.
- the neurosignal also includes an instruction set for proper organ function.
- a respiratory neurosignal would thus include an instruction set for the diaphragm to perform an efficient ventilation, including information regarding frequency, initial muscle tension, degree (or depth) of muscle movement, etc.
- Neurosignals or "neuro-electrical coded signals” are thus codes that contain complete sets of information for complete organ function.
- a generated nerve-specific instruction i.e., signal(s)
- respiration and, hence, treat a multitude of respiratory system disorders include, but are not limited to, sleep apnea, asthma, excessive mucus production, acute bronchitis and emphysema.
- sleep apnea is generally defined as a temporary cessation of respiration during sleep.
- Obstructive sleep apnea is the recurrent occlusion of the upper airways of the respiratory system during sleep.
- Central sleep apnea occurs when the brain fails to send the appropriate signals to the breathing muscles to initiate respirations during sleep.
- Those afflicted with sleep apnea experience sleep fragmentation and complete or nearly complete cessation of respiration (or ventilation) during sleep with potentially severe degrees of oxyhemoglobin desaturation.
- a system and method for providing respiratory assistance includes the step of recording "breathing signals", which are generated in the respiratory center of a patient.
- the “breathing signals” are processed and employed to control a muscle stimulation apparatus or ventilator.
- a system and method for treating sleep apnea is disclosed.
- the noted system includes respiration sensor that is adapted to capture neuro- electrical signals and extract the signal components related to respiration.
- the signals are similarly processed and employed to control a ventilator.
- control signals that are generated and transmitted are "user determined” and “device determinative".
- control signals are thus not related to or representative of the signals that are generated in the body and, hence, would not be operative in the control or modulation of the respiratory system if transmitted thereto.
- the method to control respiration generally comprises (i) generating at least a first simulated neuro-electrical coded signal that is recognizable by the respiration system as a modulation signal and (ii) transmitting the first simulated neuro-electrical coded signal to the body to control the respiratory system.
- the simulated neuro-electrical coded signal comprises a frequency modulated signal.
- the simulated neuro- electrical coded signal is modulated within a predetermined signal envelope.
- the signal envelope includes a positive voltage region that transitions from an initial voltage equal to approximately zero (0) to a maximum voltage region at a first period of time to a decreased voltage equal to approximately zero (0) at a second period of time, and a negative voltage region that substantially corresponds to the positive voltage region.
- the simulated neuro-electrical coded signal is frequency modulated within the signal envelope at a frequency in the range of approximately 50 - 1000 Hz.
- the maximum voltage or peak amplitude of the modulated neuro- electrical coded signal is in the range of approximately 100 mV to 20 V.
- the time at peak voltage or amplitude is in the range of approximately 50 msec to 2.0 sec.
- the simulated neuro-electrical coded signal is transmitted to the subject's nervous system. In another embodiment, the simulated neuro-electrical coded signal is transmitted proximate to a target zone on the neck, head or thorax.
- the method for controlling respiration in a subject generally comprises (i) generating at least a first simulated neuro-electrical coded signal that is recognizable by the respiratoiy system as a modulation signal, (ii) monitoring the respiration status of the subject and providing at least one respiratory system status signal in response to an abnormal function of the respiratory system, (iii) transmitting the first simulated neuro-electrical coded signal to the body in response to a respiratory status signal that is indicative of respiratory distress or a respiratory abnormality.
- FIGURES IA and IB are illustrations of waveform signals captured from the body that are operative in the control of the respiratory system
- FIGURE 2 is a schematic illustration of one embodiment of a respiratory control system, according to the invention.
- FIGURE 3 is a schematic illustration of another embodiment of a respiratory control system, according to the invention.
- FIGURE 4 is a schematic illustration of yet another embodiment of a respiratory control system, according to the invention.
- FIGURES 5A and 5B are illustrations of simulated waveform signals that have been generated by the process means of the invention
- FIGURE 6 is a schematic illustration of an embodiment of a respiratory control system that can be employed in the treatment of sleep apnea, according to the invention
- FIGURE 7 is an illustration of a waveform signal captured from the phrenic nerve that is operative in the control of the respiratory system and a signal envelope associated therewith, according to the invention
- FIGURE 8 is an illustration of one embodiment of a signal envelope of the invention.
- FIGURE 8 is an illustration of one embodiment of a simulated neuro-electrical coded signal of the invention.
- neural system means and includes the central nervous system, including the spinal cord, medulla, pons, cerebellum, midbrain, diencephalon and cerebral hemisphere, and the peripheral nervous system, including the neurons and glia.
- waveform and waveform signal mean and include a composite electrical signal that is generated in the body and carried by neurons in the body, including neurocodes, neurosignals and components and segments thereof.
- simulated waveform signal means an electrical signal that substantially corresponds to a "waveform signal”.
- signal envelope means the envelope or area defined by a “waveform signal” or portion thereof (i.e., signal segment).
- simulated neuro-electrical coded signal means an electrical signal that is modulated within a “signal envelope”.
- signal train means a composite signal having a plurality of signals, such as the "simulated neuro-electrical coded signal” and "simulated waveform” signals defined above.
- the simulated neuro-electrical coded signals that are generated by the process means of the invention are designed and adapted to be transmitted continuously or at set intervals to a subject.
- respiration means the process of breathing.
- respiratory system means and includes, without limitation, the organs subserving the function of respiration, including the diaphragm, lungs, nose, throat, larynx, trachea and bronchi, and the nervous system associated therewith.
- target zone means and includes, without limitation, a region of the body proximal to a portion of the nervous system whereon the application of electrical signals can induce the desired neural control without the direct application (or conduction) of the signals to a target nerve.
- patient and “subject”, as used herein, mean and include humans and animals.
- plexus means and includes a branching or tangle of nerve fibers outside the central nervous system.
- ganglion means and includes a group or groups of nerve cell bodies located outside the central nervous system.
- respiration rate means and includes the temporary cessation of respiration or a reduction in the respiration rate.
- respiratory system disorder mean and include any dysfunction of the respiratory system that impedes the normal respiration process. Such dysfunction can be caused by a multitude of known factors and events, including spinal cord injury and severance.
- the method for controlling respiration in a subject generally comprises generating at least one simulated neuro-electrical coded signal that is recognizable by the subject's respiratory system as a modulation signal and transmitting the simulated neuro-electrical coded signal to the subject's body.
- the simulated neuro-electrical coded signal is transmitted to the subject's nervous system.
- neuro-electrical signals related to respiration originate in the respiratory center of the medulla oblongata. These signals can be captured or collected from the respiratory center or along the nerves carrying the signals to the respiratory musculature.
- the phrenic nerve has, however, proved particularly suitable for capturing the noted signals.
- Figs. IA and IB there are shown exemplar waveform signals that are operative in the efferent operation of the human (and animal) diaphragm; Fig. IA showing three (3) signals 1OA, 1OB, 1OC, having rest periods 12A, 12B therebetween, and Fig. IB showing an expanded view of signal 1OB.
- the noted signals traverse the phrenic nerve, which runs between the cervical spine and the diaphragm.
- signals 1OA, 1OB, 1OC will vary as a function of various factors, such as physical exertion, reaction to changes in the environment, etc.
- the presence, shape and number of pulses of signal segment 14 can similarly vary from muscle (or muscle group) signal-to-signal.
- the noted signals include coded information related to inspiration, such as frequency, initial muscle tension, degree (or depth) of muscle movement, etc.
- neuro-electrical signals generated in the body that are operative in the control of respiration are captured and transmitted to a processor or control module.
- control module includes storage means adapted to store the captured signals.
- control module is further adapted to store the components of the captured signals (that are extracted by the processor) in the storage means according to the function performed by the signal components.
- the stored signals can subsequently be employed to establish base-line respiration signals.
- the module can then be programmed to compare "abnormal" respiration signals (and components thereof) captured from a subject and, as discussed below, generate a simulated waveform or simulated neuro-electrical coded signal (discussed below) or modified base-line signal for transmission to the subject.
- Such modification can include, for example, increasing the amplitude of a respiratory signal, increasing the rate of the signals, etc.
- the captured neuro-electrical signals are processed by known means and a simulated waveform signal (or simulated neuro-electrical coded signal) that is representative of at least one captured neuro-electrical signal and is operative in the control of respiration (i.e., recognized by the brain or respiratory system as a modulation signal) is generated by the control module.
- a simulated waveform signal or simulated neuro-electrical coded signal
- respiration i.e., recognized by the brain or respiratory system as a modulation signal
- the simulated signal is similarly stored in the storage means of the control module.
- the simulated waveform signal (or simulated neuro-electrical coded signal) is accessed from the storage means and transmitted to the subject via a transmitter (or probe).
- the applied voltage of the simulated waveform signal can be up to 20 volts to allow for voltage loss during the transmission of the signals.
- current is maintained to less than 2 amp output.
- Direct conduction into the nerves via electrodes connected directly to such nerves preferably have outputs less than 3 volts and current less than one tenth of an amp.
- the control system 2OA includes a control module 22, which is adapted to receive neuro-electrical coded signals or "waveform signals" from a signal sensor (shown in phantom and designated 21) that is in communication with a subject, and at least one treatment member 24.
- a control module 22 which is adapted to receive neuro-electrical coded signals or "waveform signals" from a signal sensor (shown in phantom and designated 21) that is in communication with a subject, and at least one treatment member 24.
- the treatment member 24 is adapted to communicate with the body and receives the simulated waveform signal or simulated neuro-electrical coded signal from the control module 22.
- the treatment member 24 can comprise an electrode, antenna, a seismic transducer, or any other suitable form of conduction attachment for transmitting respiratory signals that regulate or operate breathing function in human or animals.
- the treatment member 24 can be attached to appropriate nerves or respiratory organ(s) via a surgical process. Such surgery can, for example, be accomplished with "key-hole" entrance in a thoracic-stereo-scope procedure. If necessary, a more expansive thoracotomy approach can be employed for more proper placement of the treatment member 24.
- the treatment member 24 can be inserted into a body cavity, such as the nose or mouth, and can be positioned to pierce the mucinous or other membranes, whereby the member 24 is placed in close proximity to the medulla oblongata and/or pons.
- the simulated signals of the invention can then be sent into nerves that are in close proximity with the brain stem.
- control module 22 and treatment member 24 can be entirely separate elements, which allow system 2OA to be operated remotely.
- the control module 22 can be unique, i.e., tailored to a specific operation and/or subject, or can comprise a conventional device.
- Fig 3 there is shown a further embodiment of a control system 2OB of the invention. As illustrated in Fig. 3, the system 2OB is similar to system 2OA shown in Fig. 2. However, in this embodiment, the control module 22 and treatment member 24 are connected.
- control system 2OC similarly includes a control module 22 and a treatment member 24.
- the system 2OC further includes at least one signal sensor 21.
- the system 20C also includes a processing module (or computer) 26.
- the processing module 26 can be a separate component or can be a subsystem of a control module 22', as shown in phantom.
- the processing module (or control module) preferably includes storage means adapted to store the captured respiratory signals.
- the processing module 26 is further adapted to extract and store the components of the captured respiratory signals in the storage means according to the function performed by the signal components.
- the method for controlling respiration in a subject includes generating a first simulated waveform signal that is recognizable by the respiratory system as a modulation signal and (ii) transmitting the first simulated waveform signal to the body to control the respiratory system.
- the method for controlling respiration comprises capturing coded waveform signals that are generated in a subject's body and are operative in the control of respiration, (ii) generating a first simulated waveform signal that is recognizable by the respiratory system as a modulation signal, and (iii) transmitting the first simulated waveform signal to the body.
- the first simulated waveform signal includes at least a second simulated waveform signal that substantially corresponds to at least one of the captured waveform signals and is operative in the control of the respiratory system.
- the first simulated waveform signal is transmitted to the subject's nervous system. In another embodiment, the first simulated waveform signal is transmitted proximate to a target zone on the neck, head or thorax.
- the simulated waveform signals can be adjusted (or modulated), if necessary, prior to transmission to the subject.
- the method to control respiration generally comprises (i) capturing coded waveform signals that are generated in the body and are operative in control of respiration and (ii) storing the captured waveform signals in a storage medium, the storage medium being adapted to store the components of the captured waveform signals according to the function performed by the signal components, (iii) generating a first simulated waveform signal that substantially corresponds to at least one of the captured waveform signals, and (iv) transmitting the first simulated waveform signal to the body to the control the respiratory system.
- the method to control respiration generally comprises (i) capturing a first plurality of waveform signals generated in a first subject's body that are operative in the control of respiration, (ii) generating a base-line respiration waveform signal from the first plurality of waveform signals, (iii) capturing a second waveform signal generated in the first subject's body that is operative in the control of respiration, (iv) comparing the base-line waveform signal to the second waveform signal, (v) generating a third waveform signal based on the comparison of the base-line and second waveform signals, and (vi) transmitting the third waveform signal to the body, the third waveform signal being operative in the control of respiration.
- the first plurality of waveform signals is captured from a plurality of subjects.
- the step of transmitting the waveform signals to the subject's body is accomplished by direct conduction or transmission through unbroken skin at a selected appropriate zone on the neck, head, or thorax. Such zone will approximate a position close to the nerve or nerve plexus onto which the signal is to be imposed.
- the step of transmitting the waveform signals to the subject's body is accomplished by direct conduction via attachment of an electrode to the receiving nerve or nerve plexus. This requires a surgical intervention to physically attach the electrode to the selected target nerve.
- the step of transmitting a signal to the subject's body is accomplished by transposing the signal into a seismic form.
- the seismic signal is then sent into a region of the head, neck, or thorax in a manner that allows the appropriate "nerve” to receive and obey the coded instructions of the seismic signal.
- simulated waveform signals 190, 191 that were generated by the apparatus and methods of the invention.
- the noted signals are merely representative of the simulated waveform signals that can be generated by the apparatus and methods of the invention and should not be interpreted as limiting the scope of the invention in any way.
- Fig. 5A there is shown the exemplar phrenic simulated waveform signal 190 showing only the positive half of the transmitted signal.
- the signal 190 comprises only two segments, the initial segment 192 and the spike segment 193.
- Fig. 5B there is shown the exemplar phrenic simulated waveform signal 191 that has been fully modulated at 500 Hz.
- the signal 191 includes the same two segments, the initial segment 194 and the spike segment 195.
- the simulated neuro-electrical coded signals of the invention comprise frequency modulated signals that are modulated within a predetermined signal envelope.
- the signal envelope is defined by and, hence, derived from a waveform signal (or segment of a waveform signal) that is generated in the body.
- a waveform signal 16 that was captured from the phrenic nerve that is operative in the control of the respiratory system.
- the signal 16 defines a signal envelope 220, which in one embodiment, is disposed proximate the signal amplitude transition points 17 (i.e., outer shape defined by the signal).
- the signal envelope 220 can represent approximately 100% of the shape defined by the signal 16, as shown in Fig. 8, or a percentage thereof.
- the signal envelope represents approximately 80% of the envelope (or shape) defined by the base signal.
- the signal envelope 220 includes a positive voltage region 222 that preferably transitions from an initial voltage equal to approximately 0 V (at to) to a maximum voltage region 226 at a first period of time (ti), i.e., to ⁇ ti to approximately 0 V at a second period of time (t 2 ), i.e., to ⁇ t 2 .
- the signal envelope 220 also includes a negative voltage region 224 that preferably substantially corresponds to the positive voltage region 222.
- ti is in the range of approximately 50 msec - 1 sec, more preferably, in the range of approximately 100 msec - 900 msec, depending on the normal breathing rate of the subject.
- t 2 is in the range of approximately 100 msec - 1 sec.
- the maximum voltage within region 226 is in the range of approximately 100 mV - 20 V, more preferably, in the range of approximately 150 mV - 2 V.
- the maximum voltage region 226 has a period of time associated therewith (designated "t 3 ”) in the range of approximately 0.0001 - 25 msec.
- the signal envelope 220 and, hence, signal modulated therein can also be modified to increase or decrease the transition time from O V to maximum voltage (or amplitude), i.e., to to t l5 the maximum voltage and/or time t 3 within the maximum voltage region and/or transition from maximum voltage to 0 V (at t 2 ).
- a simulated neuro- electrical coded signal 230 which has been modulated at 500 Hz within signal envelope 220.
- the simulated neuro-electrical coded signals can be modulated within a signal envelope at a multitude of frequencies.
- the simulated neuro-electrical coded signals of the invention are frequency modulated within a signal envelope at a frequency in the range of approximately 50 - 1000 Hz for a period of time, i.e., to -t 2 , in the range of approximately 400 msec to 2.0 sec.
- the noted time will depend on the normal breathing rate of the subject.
- the simulated neuro-electrical coded signal is frequency modulated within a signal envelope at a frequency in the range of approximately 50 - 300 Hz for a period of time in the range of approximately 0.5 - 1.0 sec.
- the simulated neuro-electrical coded signals of the invention can be employed to construct "signal trains", comprising a plurality of simulated neuro-electrical coded signals.
- the signal train can comprise a continuous train of simulated neuro-electrical coded signals or can included interposed signals or rest periods, i.e., zero voltage and current, between one or more simulated neuro-electrical coded signals.
- the signal train can also comprise substantially similar simulated neuro-electrical coded signals, different simulated neuro-electrical coded signals, e.g., modulated within different signal envelopes, or a combination thereof.
- the method for controlling respiration in a subject thus includes generating at least a first simulated neuro-electrical coded signal that is recognizable by the respiratory system as a modulation signal and (ii) transmitting the first simulated neuro-electrical coded signal to the body to control the respiratory system.
- the first simulated neuro-electrical coded signal is transmitted to the subject's nervous system. In another embodiment, the first simulated neuro-electrical coded signal is transmitted proximate to a target zone on the neck, head or thorax.
- the method for controlling respiration in a subject includes generating a first signal train, said signal train including a plurality of simulated neuro-electrical coded signals that are recognizable by the respiratory system as modulation signals and (ii) transmitting the first signal train to the body to control the respiratory system.
- the control of respiration can, in some instances, require sending one or more simulated neuro-electrical coded signals into one or more nerves, including up to eight nerves simultaneously, to control respiration rates and depth of inhalation.
- the correction of asthma or other breathing impairment or disease involves the rhythmic operation of the diaphragm and/or the intercostal muscles to inspire and expire air for the extraction of oxygen and the dumping of waste gaseous compounds, such as carbon dioxide.
- opening (dilation) the bronchial tubular network allows for more air volume to be exchanged and processed for its oxygen content within the lungs.
- the dilation process can be controlled by transmission of the signals of the invention.
- the bronchi can also be closed down to restrict air volume passage into the lungs.
- a balance of controlling nerves for dilation and/or constriction can thus be accomplished through the methods and apparatus of the invention.
- mucus production if excessive, can form mucoid plugs that restrict air volume flow throughout the bronchi. As is known in the art, no mucus is produced by the lung except in the lumen of the bronchi and also in the trachea.
- the noted mucus production can, however, be increased or decreased by transmission of the signals of the invention.
- the transmission of the aforementioned signals of the invention can thus balance the quality and quantity of the mucus.
- the present invention thus provides methods and apparatus to effectively control respiration rates and strength, along with bronchial tube dilation and mucinous action in the bronchi, by generating and transmitting simulated neuro-electrical coded signals to the body.
- Such ability to open bronchi will be useful for emergency room treatment of acute bronchitis or smoke inhalation injuries.
- Chronic airway obstructive disorders, such as emphysema can also be addressed.
- Acute fire or chemical inhalation injury treatment can also be enhanced through the methods and apparatus of the invention, while using mechanical respiration support.
- Traum-mediated mucus secretions also lead to obstruction of the airways and are refractory to urgent treatment, posing a life-threatening risk.
- Edema (swelling) inside the trachea or bronchial tubes tends to limit bore size and cause oxygen starvation.
- the ability to open bore size is essential or at least desirable during treatment.
- the effort of breathing in patients with pneumonia may be eased by modulated activation of the phrenic nerve through the methods and apparatus of the invention.
- Treatment of numerous other life threatening conditions also revolves around a well functioning respiratory system. Therefore, the invention provides the physician with a method to open bronchi and fine tune the breathing rate to improve oxygenation of patients.
- This electronic treatment method (in one embodiment) encompasses the transmission of activating or suppressing simulated neuro-electrical coded signals onto selected nerves to improve respiration. According to the invention, such treatments could be augmented by oxygen administration and the use of respiratory medications, which are presently available.
- the methods and apparatus of the invention can also be effectively employed in the treatment of obstructive sleep apnea (or central sleep apnea) and other respiratory ailments.
- a respiratory control system 30 that can be employed in the treatment of sleep apnea.
- the system 30 includes at least one respiration sensor 32 that is adapted to monitor the respiration status of a subject and transmit at least one signal indicative of the respiratory status.
- the respiration status (and, hence, a sleep disorder) can be determined by a multitude of factors, including diaphragm movement, respiration rate, levels of O 2 and/or CO 2 in the blood, muscle tension in the neck, air passage (or lack thereof) in the air passages of the throat or lungs, i.e., ventilation.
- Various sensors can thus be employed within the scope of the invention to detect the noted factors and, hence, the onset of a respiratory disorder.
- the system 30 further includes a processor 36, which is adapted to receive the respiratory system status signal(s) from the respiratory sensor 32.
- the processor 36 is further adapted to receive coded waveform signals recorded by a respiratory signal probe (shown in phantom and designated 34).
- the processor 36 includes storage means for storing the captured, coded waveform signals and respiratory system status signals.
- the processor 36 is further adapted to extract the components of the waveform signals and store the signal components in the storage means.
- the processor 36 is programmed to detect respiratory system status signals indicative of respiration abnormalities and/or waveform signal components indicative of respiratory system distress and generate at least one simulated neuro-electrical coded signal that is operative in the control of respiration.
- the simulated neuro-electrical coded signal is routed to a transmitter 38 that is adapted to be in communication with the subject's body.
- the transmitter 38 is adapted to transmit the simulated neuro-electrical coded signal to the subject's body (in a similar manner as described above) to control and, preferably, remedy the detected respiration abnormality.
- the simulated neuro-electrical coded signal is preferably transmitted to the phrenic nerve to contract the diaphragm, to the hypoglossal nerve to tighten the throat muscles and/or to the vagus nerve to maintain normal brainwave patterns.
- a single signal or a plurality of signals can be transmitted in conjunction with one another.
- the method for controlling respiration in a subject generally comprises (i) generating at least a first simulated neuro-electrical coded signal that is recognizable by the respiratory system as a modulation signal, (ii) monitoring the respiration status of the subject and providing at least one respiratory system status signal in response to an abnormal function of the respiratory system, (iii) transmitting the simulated neuro-electrical coded signal to the body to control the respiration system in response to a respiration status signal that is indicative of respiratory distress or a respiratory abnormality.
- Example 1 Three swine were subjected to various frequency modulated, simulated neuro- electrical coded signals. Four signals having four different modulation periods were employed; 400 msec, 800 msec, 1.2 sec and 2.0 sec. The voltage levels for the each signal were as follows: +/- 200 mV, +/- 230 mV and +/- 250 mV. Each signal was modulated within a signal envelope substantially similar to the envelope shown in Fig. 8, at a frequency of approximately 500 Hz.
- tidal volumes, oxygen saturation, and end- tidal CO 2 levels vary, depending on the period of time of signal transmitted and the voltage at which the signal is transmitted.
- maximal tidal volume was achieved with a signal of 800 msec and a voltage of +/-250 mV.
- Maximal oxygen levels were achieved with a signal of 1.2 sec and a voltage of +/-230 mV.
- Minimal CO 2 levels were achieved with a signal of 400 msec and a voltage of +/-200 mV.
- simulated neuro-electrical coded signals of the invention can be modified to achieve the desired results, whether to increase or decrease tidal volume, maximize oxygen levels or minimize carbon dioxide levels or some combination thereof.
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2008541143A JP2009502449A (en) | 2005-05-13 | 2006-03-06 | Method and system for controlling respiration with a pseudo-neuroelectrically encoded signal |
EP06737164A EP1940504A4 (en) | 2005-05-13 | 2006-03-06 | Method and system to control respiration by means of simulated neuro-electrical coded signals |
AU2006339492A AU2006339492A1 (en) | 2003-05-16 | 2006-03-06 | Method and system to control respiration by means of simulated neuro-electrical coded signals |
CA002608613A CA2608613A1 (en) | 2005-05-13 | 2006-03-06 | Method and system to control respiration by means of simulated neuro-electrical coded signals |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/129,264 | 2005-05-13 | ||
US11/129,264 US20050261747A1 (en) | 2003-05-16 | 2005-05-13 | Method and system to control respiration by means of neuro-electrical coded signals |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2008051176A1 true WO2008051176A1 (en) | 2008-05-02 |
Family
ID=39103168
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2006/007952 WO2008051176A1 (en) | 2003-05-16 | 2006-03-06 | Method and system to control respiration by means of simulated neuro-electrical coded signals |
PCT/US2006/007953 WO2008051177A1 (en) | 2003-05-16 | 2006-03-06 | Controlling respiration by stimulated action potential signals |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2006/007953 WO2008051177A1 (en) | 2003-05-16 | 2006-03-06 | Controlling respiration by stimulated action potential signals |
Country Status (5)
Country | Link |
---|---|
US (1) | US20050261747A1 (en) |
EP (2) | EP1937355A4 (en) |
JP (2) | JP2009502449A (en) |
CA (2) | CA2608613A1 (en) |
WO (2) | WO2008051176A1 (en) |
Families Citing this family (82)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040226556A1 (en) | 2003-05-13 | 2004-11-18 | Deem Mark E. | Apparatus for treating asthma using neurotoxin |
US8160711B2 (en) | 2003-10-15 | 2012-04-17 | Rmx, Llc | Multimode device and method for controlling breathing |
US7979128B2 (en) | 2003-10-15 | 2011-07-12 | Rmx, Llc | Device and method for gradually controlling breathing |
US7970475B2 (en) | 2003-10-15 | 2011-06-28 | Rmx, Llc | Device and method for biasing lung volume |
US8467876B2 (en) | 2003-10-15 | 2013-06-18 | Rmx, Llc | Breathing disorder detection and therapy delivery device and method |
US9259573B2 (en) | 2003-10-15 | 2016-02-16 | Rmx, Llc | Device and method for manipulating exhalation |
US8140164B2 (en) | 2003-10-15 | 2012-03-20 | Rmx, Llc | Therapeutic diaphragm stimulation device and method |
US8265759B2 (en) | 2003-10-15 | 2012-09-11 | Rmx, Llc | Device and method for treating disorders of the cardiovascular system or heart |
US8244358B2 (en) * | 2003-10-15 | 2012-08-14 | Rmx, Llc | Device and method for treating obstructive sleep apnea |
US7346382B2 (en) | 2004-07-07 | 2008-03-18 | The Cleveland Clinic Foundation | Brain stimulation models, systems, devices, and methods |
US9339650B2 (en) | 2005-04-13 | 2016-05-17 | The Cleveland Clinic Foundation | Systems and methods for neuromodulation using pre-recorded waveforms |
US8112154B2 (en) * | 2005-04-13 | 2012-02-07 | The Cleveland Clinic Foundation | Systems and methods for neuromodulation using pre-recorded waveforms |
US7644714B2 (en) | 2005-05-27 | 2010-01-12 | Apnex Medical, Inc. | Devices and methods for treating sleep disorders |
US8041428B2 (en) | 2006-02-10 | 2011-10-18 | Electrocore Llc | Electrical stimulation treatment of hypotension |
US8812112B2 (en) | 2005-11-10 | 2014-08-19 | ElectroCore, LLC | Electrical treatment of bronchial constriction |
US9037247B2 (en) | 2005-11-10 | 2015-05-19 | ElectroCore, LLC | Non-invasive treatment of bronchial constriction |
AU2006315829B2 (en) | 2005-11-10 | 2011-01-27 | ElectroCore, LLC. | Electrical stimulation treatment of bronchial constriction |
CN101400403A (en) | 2006-02-10 | 2009-04-01 | 电子核心公司 | Methods and apparatus for treating anaphylaxis using electrical modulation |
JP2009525806A (en) | 2006-02-10 | 2009-07-16 | エレクトロコア、インコーポレイテッド | Electrical stimulation treatment for hypotension |
EP2478931B1 (en) | 2006-10-13 | 2015-12-30 | Cyberonics, Inc. | Obstructive sleep apnea treatment device |
US9744354B2 (en) | 2008-12-31 | 2017-08-29 | Cyberonics, Inc. | Obstructive sleep apnea treatment devices, systems and methods |
US9205262B2 (en) | 2011-05-12 | 2015-12-08 | Cyberonics, Inc. | Devices and methods for sleep apnea treatment |
US9913982B2 (en) | 2011-01-28 | 2018-03-13 | Cyberonics, Inc. | Obstructive sleep apnea treatment devices, systems and methods |
US8855771B2 (en) | 2011-01-28 | 2014-10-07 | Cyberonics, Inc. | Screening devices and methods for obstructive sleep apnea therapy |
US9186511B2 (en) | 2006-10-13 | 2015-11-17 | Cyberonics, Inc. | Obstructive sleep apnea treatment devices, systems and methods |
US8280513B2 (en) | 2006-12-22 | 2012-10-02 | Rmx, Llc | Device and method to treat flow limitations |
WO2009048610A1 (en) | 2007-10-10 | 2009-04-16 | Cardiac Pacemakers, Inc. | Respiratory stimulation for treating periodic breathing |
US9220889B2 (en) | 2008-02-11 | 2015-12-29 | Intelect Medical, Inc. | Directional electrode devices with locating features |
US8019440B2 (en) | 2008-02-12 | 2011-09-13 | Intelect Medical, Inc. | Directional lead assembly |
US8483831B1 (en) | 2008-02-15 | 2013-07-09 | Holaira, Inc. | System and method for bronchial dilation |
AU2009244058B2 (en) | 2008-05-09 | 2015-07-02 | Nuvaira, Inc | Systems, assemblies, and methods for treating a bronchial tree |
US9272153B2 (en) | 2008-05-15 | 2016-03-01 | Boston Scientific Neuromodulation Corporation | VOA generation system and method using a fiber specific analysis |
WO2009140636A2 (en) | 2008-05-15 | 2009-11-19 | Inspire Medical Systems, Inc. | Method and apparatus for sensing respiratory pressure in an implantable stimulation system |
WO2010039853A1 (en) | 2008-10-01 | 2010-04-08 | Inspire Medical Systems, Inc. | Transvenous method of treating sleep apnea |
EP2389224B1 (en) | 2008-11-19 | 2017-03-01 | Inspire Medical Systems, Inc. | Device treating sleep disordered breathing |
US9486628B2 (en) | 2009-03-31 | 2016-11-08 | Inspire Medical Systems, Inc. | Percutaneous access for systems and methods of treating sleep apnea |
EP2470258B1 (en) | 2009-08-27 | 2017-03-15 | The Cleveland Clinic Foundation | System and method to estimate region of tissue activation |
CN107049479B (en) | 2009-10-27 | 2020-10-16 | 努瓦拉公司 | Delivery device with coolable energy emitting assembly |
JP6000851B2 (en) | 2009-11-11 | 2016-10-05 | ホライラ, インコーポレイテッド | Systems, devices, and methods for tissue treatment and stenosis control |
US8911439B2 (en) | 2009-11-11 | 2014-12-16 | Holaira, Inc. | Non-invasive and minimally invasive denervation methods and systems for performing the same |
WO2011068997A1 (en) | 2009-12-02 | 2011-06-09 | The Cleveland Clinic Foundation | Reversing cognitive-motor impairments in patients having a neuro-degenerative disease using a computational modeling approach to deep brain stimulation programming |
EP2580710B1 (en) | 2010-06-14 | 2016-11-09 | Boston Scientific Neuromodulation Corporation | Programming interface for spinal cord neuromodulation |
US9207845B2 (en) | 2011-03-29 | 2015-12-08 | Boston Scientific Neuromodulation Corporation | System and method for atlas registration |
US9592389B2 (en) | 2011-05-27 | 2017-03-14 | Boston Scientific Neuromodulation Corporation | Visualization of relevant stimulation leadwire electrodes relative to selected stimulation information |
US8918183B2 (en) | 2011-08-09 | 2014-12-23 | Boston Scientific Neuromodulation Corporation | Systems and methods for stimulation-related volume analysis, creation, and sharing |
WO2013023218A1 (en) | 2011-08-11 | 2013-02-14 | Inspire Medical Systems, Inc. | System for selecting a stimulation protocol based on sensed respiratory effort |
US8934992B2 (en) | 2011-09-01 | 2015-01-13 | Inspire Medical Systems, Inc. | Nerve cuff |
EP2819745B1 (en) | 2012-02-29 | 2018-10-10 | The Cleveland Clinic Foundation | System and method for generating composite patterns of stimulation or waveforms |
EP2879757B1 (en) | 2012-08-04 | 2019-06-26 | Boston Scientific Neuromodulation Corporation | Systems and methods for storing and transferring registration, atlas, and lead information between medical devices |
EP2890451B1 (en) | 2012-08-28 | 2021-09-22 | Boston Scientific Neuromodulation Corporation | Parameter visualization, selection, and annotation interface |
US9792412B2 (en) | 2012-11-01 | 2017-10-17 | Boston Scientific Neuromodulation Corporation | Systems and methods for VOA model generation and use |
US9398933B2 (en) | 2012-12-27 | 2016-07-26 | Holaira, Inc. | Methods for improving drug efficacy including a combination of drug administration and nerve modulation |
US11383083B2 (en) | 2014-02-11 | 2022-07-12 | Livanova Usa, Inc. | Systems and methods of detecting and treating obstructive sleep apnea |
US9959388B2 (en) | 2014-07-24 | 2018-05-01 | Boston Scientific Neuromodulation Corporation | Systems, devices, and methods for providing electrical stimulation therapy feedback |
US10265528B2 (en) | 2014-07-30 | 2019-04-23 | Boston Scientific Neuromodulation Corporation | Systems and methods for electrical stimulation-related patient population volume analysis and use |
US10272247B2 (en) | 2014-07-30 | 2019-04-30 | Boston Scientific Neuromodulation Corporation | Systems and methods for stimulation-related volume analysis, creation, and sharing with integrated surgical planning and stimulation programming |
WO2016033245A1 (en) | 2014-08-26 | 2016-03-03 | Rmx, Llc | Devices and methods for reducing intrathoracic pressure |
EP3204112A1 (en) | 2014-10-07 | 2017-08-16 | Boston Scientific Neuromodulation Corporation | Systems, devices, and methods for electrical stimulation using feedback to adjust stimulation parameters |
EP3881892A1 (en) | 2015-03-19 | 2021-09-22 | Inspire Medical Systems, Inc. | Stimulation for treating sleep disordered breathing |
WO2016191436A1 (en) | 2015-05-26 | 2016-12-01 | Boston Scientific Neuromodulation Corporation | Systems and methods for analyzing electrical stimulation and selecting or manipulating volumes of activation |
US10780283B2 (en) | 2015-05-26 | 2020-09-22 | Boston Scientific Neuromodulation Corporation | Systems and methods for analyzing electrical stimulation and selecting or manipulating volumes of activation |
WO2017003946A1 (en) | 2015-06-29 | 2017-01-05 | Boston Scientific Neuromodulation Corporation | Systems and methods for selecting stimulation parameters based on stimulation target region, effects, or side effects |
EP3280491B1 (en) | 2015-06-29 | 2023-03-01 | Boston Scientific Neuromodulation Corporation | Systems for selecting stimulation parameters by targeting and steering |
US11154238B2 (en) | 2015-08-07 | 2021-10-26 | Electroceuticals, Llc | Systems, methods and apparatuses for providing bioelectronic neurocode-based therapies to mammals |
US10071249B2 (en) | 2015-10-09 | 2018-09-11 | Boston Scientific Neuromodulation Corporation | System and methods for clinical effects mapping for directional stimulation leads |
US10716942B2 (en) | 2016-04-25 | 2020-07-21 | Boston Scientific Neuromodulation Corporation | System and methods for directional steering of electrical stimulation |
EP3458152B1 (en) | 2016-06-24 | 2021-04-21 | Boston Scientific Neuromodulation Corporation | Systems and methods for visual analytics of clinical effects |
US10350404B2 (en) | 2016-09-02 | 2019-07-16 | Boston Scientific Neuromodulation Corporation | Systems and methods for visualizing and directing stimulation of neural elements |
US10780282B2 (en) | 2016-09-20 | 2020-09-22 | Boston Scientific Neuromodulation Corporation | Systems and methods for steering electrical stimulation of patient tissue and determining stimulation parameters |
US10603498B2 (en) | 2016-10-14 | 2020-03-31 | Boston Scientific Neuromodulation Corporation | Systems and methods for closed-loop determination of stimulation parameter settings for an electrical simulation system |
EP3515548B1 (en) | 2017-01-03 | 2021-03-17 | Boston Scientific Neuromodulation Corporation | Systems and methods for selecting mri-compatible stimulation parameters |
US10589104B2 (en) | 2017-01-10 | 2020-03-17 | Boston Scientific Neuromodulation Corporation | Systems and methods for creating stimulation programs based on user-defined areas or volumes |
US10625082B2 (en) | 2017-03-15 | 2020-04-21 | Boston Scientific Neuromodulation Corporation | Visualization of deep brain stimulation efficacy |
WO2018187090A1 (en) | 2017-04-03 | 2018-10-11 | Boston Scientific Neuromodulation Corporation | Systems and methods for estimating a volume of activation using a compressed database of threshold values |
WO2019014224A1 (en) | 2017-07-14 | 2019-01-17 | Boston Scientific Neuromodulation Corporation | Systems and methods for estimating clinical effects of electrical stimulation |
US11298540B2 (en) | 2017-08-11 | 2022-04-12 | Inspire Medical Systems, Inc. | Cuff electrode |
EP3634569A1 (en) | 2017-08-15 | 2020-04-15 | Boston Scientific Neuromodulation Corporation | Systems and methods for controlling electrical stimulation using multiple stimulation fields |
JP7295141B2 (en) | 2018-04-27 | 2023-06-20 | ボストン サイエンティフィック ニューロモデュレイション コーポレイション | Multimodal electrical stimulation system and methods of making and using |
WO2019210214A1 (en) | 2018-04-27 | 2019-10-31 | Boston Scientific Neuromodulation Corporation | Systems for visualizing and programming electrical stimulation |
US11266838B1 (en) | 2019-06-21 | 2022-03-08 | Rmx, Llc | Airway diagnostics utilizing phrenic nerve stimulation device and method |
CA3208404A1 (en) * | 2021-02-17 | 2022-08-25 | Konstantinos Raymondos | Stimulation methods for an electromagnetically or electrically controlled spontaneous respiration |
CA3223250A1 (en) * | 2021-06-23 | 2022-12-29 | Stimit Ag | Stimulation methods for an electromagnetically or electrically controlled spontaneous respiration |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020072781A1 (en) * | 1999-05-05 | 2002-06-13 | Respironics, Inc. | Vestibular stimulation system and method |
US6587726B2 (en) * | 1998-06-11 | 2003-07-01 | Cprx Llc | Stimulatory device and methods to electrically stimulate the phrenic nerve |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2566276B1 (en) * | 1984-06-21 | 1988-07-08 | Medtronic Bv | DIAPHRAGMATIC STIMULATION METHOD AND APPARATUS |
GB8510832D0 (en) * | 1985-04-29 | 1985-06-05 | Bio Medical Res Ltd | Electrical stimulation of muscle |
US5056519A (en) * | 1990-05-14 | 1991-10-15 | Vince Dennis J | Unilateral diaphragmatic pacer |
US5335657A (en) * | 1991-05-03 | 1994-08-09 | Cyberonics, Inc. | Therapeutic treatment of sleep disorder by nerve stimulation |
US7280873B2 (en) * | 1995-10-27 | 2007-10-09 | Esd, Llc | Treatment of oropharyngeal disorders by application of neuromuscular electrical stimulation |
WO1997038751A1 (en) * | 1996-04-12 | 1997-10-23 | Siemens Aktiengesellschaft | Transcutaneous nerve stimulator |
SE9603841D0 (en) * | 1996-10-18 | 1996-10-18 | Pacesetter Ab | A tissue stimulating apparatus |
SE9802335D0 (en) * | 1998-06-30 | 1998-06-30 | Siemens Elema Ab | Breathing Help System |
US6633779B1 (en) * | 2000-11-27 | 2003-10-14 | Science Medicus, Inc. | Treatment of asthma and respiratory disease by means of electrical neuro-receptive waveforms |
JP2007500576A (en) * | 2003-05-16 | 2007-01-18 | サイエンス・メディカス・インコーポレイテッド | Respiration control using neuro-electrically encoded signals |
US7149574B2 (en) * | 2003-06-09 | 2006-12-12 | Palo Alto Investors | Treatment of conditions through electrical modulation of the autonomic nervous system |
WO2005009291A2 (en) * | 2003-07-23 | 2005-02-03 | Synapse Biomedical, Inc. | System and method for conditioning a diaphragm of a patient |
JP2008513049A (en) * | 2004-06-10 | 2008-05-01 | サイエンス・メディカス・インコーポレイテッド | Method and apparatus for processing a neuroelectric waveform signal |
-
2005
- 2005-05-13 US US11/129,264 patent/US20050261747A1/en not_active Abandoned
-
2006
- 2006-03-06 CA CA002608613A patent/CA2608613A1/en not_active Abandoned
- 2006-03-06 EP EP06737165A patent/EP1937355A4/en not_active Withdrawn
- 2006-03-06 WO PCT/US2006/007952 patent/WO2008051176A1/en active Application Filing
- 2006-03-06 EP EP06737164A patent/EP1940504A4/en not_active Withdrawn
- 2006-03-06 CA CA002608849A patent/CA2608849A1/en not_active Abandoned
- 2006-03-06 JP JP2008541143A patent/JP2009502449A/en active Pending
- 2006-03-06 WO PCT/US2006/007953 patent/WO2008051177A1/en active Application Filing
- 2006-03-06 JP JP2008541144A patent/JP2008545516A/en active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6587726B2 (en) * | 1998-06-11 | 2003-07-01 | Cprx Llc | Stimulatory device and methods to electrically stimulate the phrenic nerve |
US20020072781A1 (en) * | 1999-05-05 | 2002-06-13 | Respironics, Inc. | Vestibular stimulation system and method |
Non-Patent Citations (1)
Title |
---|
See also references of EP1940504A4 * |
Also Published As
Publication number | Publication date |
---|---|
EP1937355A1 (en) | 2008-07-02 |
WO2008051177A1 (en) | 2008-05-02 |
CA2608849A1 (en) | 2006-11-13 |
EP1940504A4 (en) | 2009-02-18 |
CA2608613A1 (en) | 2006-11-13 |
JP2008545516A (en) | 2008-12-18 |
JP2009502449A (en) | 2009-01-29 |
EP1940504A1 (en) | 2008-07-09 |
US20050261747A1 (en) | 2005-11-24 |
EP1937355A4 (en) | 2009-02-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20060224209A1 (en) | Method and system to control respiration by means of simulated neuro-electrical coded signals | |
US20050261747A1 (en) | Method and system to control respiration by means of neuro-electrical coded signals | |
US20060064137A1 (en) | Method and system to control respiration by means of simulated action potential signals | |
AU2002365417B2 (en) | Treatment of asthma and respiratory disease by means of electrical neuro-receptive waveforms | |
US6937903B2 (en) | Respiratory control by means of neuro-electrical coded signals | |
US20060287679A1 (en) | Method and system to control respiration by means of confounding neuro-electrical signals | |
US20050261601A1 (en) | Method and system for processing neuro-electrical waveform signals | |
WO2006124023A1 (en) | Method and system to control respiration by means of neuro-electrical coded signals | |
US20080275525A1 (en) | Method and system for regulating respiration by means of simulated action potential signals | |
MX2007013995A (en) | Method and system to control respiration by means of simulated neuro-electrical coded signals | |
MX2007013975A (en) | Controlling respiration by stimulated action potential signals |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 2006339492 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/a/2007/013995 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008541143 Country of ref document: JP |
|
ENP | Entry into the national phase |
Ref document number: 2608613 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006737164 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 06737164 Country of ref document: EP Kind code of ref document: A1 |